



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



Vonafexor

Cat. No.:	HY-109197
CAS No.:	1192171-69-9
Molecular Formula:	C ₁₉ H ₁₅ Cl ₃ N ₂ O ₅ S
Molecular Weight:	489.76
Target:	FXR; HBV
Pathway:	Metabolic Enzyme/Protease; Anti-infection
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 83.33 mg/mL (170.14 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	2.0418 mL	10.2091 mL	20.4182 mL
		5 mM	0.4084 mL	2.0418 mL	4.0836 mL
		10 mM	0.2042 mL	1.0209 mL	2.0418 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.25 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.25 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil				
	Solubility: ≥ 2.08 mg/mL (4.25 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Vonafexor (EYP001) is an orally active, non-steroidal and selective FXR agonist. Vonafexor shows significant HBsAg reduction when combined with Peg-IFNα. Vonafexor can be used for anti-HBV research ^{[1][2]} .
In Vitro	Vonafexor (EYP001) inhibits the HBV replication cycle in HepaRG cells resulting in significant reductions in HBV DNA, HBsAg and HBeAg secretion, with additive effects when combined with Entecavir (HY-13623) or Tenofovir (HY-13910) ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Biochem Pharmacol. 2023 Feb 13;209:115452.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Erken R, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat. 2021 Dec;28(12):1690-1698.
- [2]. Hui RW, et al. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022 Jun;27(2):127-140.
- [3]. Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66(1):S690.
- [4]. Fiorucci S, et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA